靶向治疗：罕见癌症范例。
Targeted therapies: the rare cancer paradigm.
机构信息
Scientific Directorate, Fondazione IRCCS - Istituto Nazionale dei Tumori Milano, Via Venezian 1, 20133 Milan, Italy.
出版信息
Mol Oncol. 2010 Feb;4(1):19-37. doi: 10.1016/j.molonc.2009.10.003. Epub 2009 Oct 28.
Abstract
This review analyzes the state of the art of targeted therapies for several tumors, starting from the paradigmatic example of Imatinib treatment in chronic myelogenous leukemia (CML). We discuss how rare tumors can be models for various mechanisms of receptor tyrosine kinase (RTK) activation, and provide the opportunity to develop new therapies also for more common cancer types. We discuss the activation of the downstream RTK effectors as further targets for therapies in colorectal cancer. Finally, we highlight how a novel multidimensional approach which adds an in silico dimension to the in vitro and in vivo approach, can predict clinical results.
摘要
这篇综述分析了几种肿瘤的靶向治疗现状，从伊马替尼治疗慢性髓性白血病（CML）的典范范例开始。我们讨论了罕见肿瘤如何成为受体酪氨酸激酶（RTK）激活各种机制的模型，并为更常见的癌症类型提供了开发新疗法的机会。我们讨论了结直肠癌中 RTK 效应器的激活作为治疗的进一步靶点。最后，我们强调了如何通过将体外和体内方法与计算维度相结合的新多维方法来预测临床结果。
相似文献
1
Targeted therapies: the rare cancer paradigm.靶向治疗：罕见癌症范例。
Mol Oncol. 2010 Feb;4(1):19-37. doi: 10.1016/j.molonc.2009.10.003. Epub 2009 Oct 28.
2
Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.Polo-like 激酶 1（Plk1）作为慢性髓性白血病的一个新的药物靶点：用 Plk1 抑制剂 BI 2536 克服伊马替尼耐药性。
Cancer Res. 2010 Feb 15;70(4):1513-23. doi: 10.1158/0008-5472.CAN-09-2181. Epub 2010 Feb 9.
3
PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.新型酪氨酸激酶抑制剂PD166326在慢性髓性白血病小鼠模型中具有比甲磺酸伊马替尼更强的抗白血病活性。
Blood. 2005 May 15;105(10):3995-4003. doi: 10.1182/blood-2004-09-3534. Epub 2005 Jan 18.
4
Mechanisms of resistance to imatinib in CML patients: a paradigm for the advantages and pitfalls of molecularly targeted therapy.慢性粒细胞白血病患者对伊马替尼耐药的机制：分子靶向治疗的优势与陷阱范例
Curr Cancer Drug Targets. 2006 Dec;6(8):645-57. doi: 10.2174/156800906779010209.
5
3. Imatinib therapy in chronic myelogenous leukemia.3. 伊马替尼治疗慢性粒细胞白血病
Intern Med. 2007;46(2):95-7. doi: 10.2169/internalmedicine.46.1781. Epub 2007 Jan 15.
6
Mutational analysis and overcoming imatinib resistance in chronic myeloid leukemia with novel tyrosine kinase inhibitors.慢性髓性白血病中新型酪氨酸激酶抑制剂的突变分析及克服伊马替尼耐药性
Curr Treat Options Oncol. 2007 Aug;8(4):287-95. doi: 10.1007/s11864-007-0036-y.
7
Which TKI should be recommended as initial treatment for CML in chronic phase?哪种酪氨酸激酶抑制剂应被推荐作为慢性期慢性髓性白血病的初始治疗药物？
Oncology (Williston Park). 2012 Oct;26(10):912, 914.
8
Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.Lyn调节伊马替尼耐药慢性粒细胞白血病细胞中的BCR-ABL和Gab2酪氨酸磷酸化以及c-Cbl蛋白稳定性。
Blood. 2008 Apr 1;111(7):3821-9. doi: 10.1182/blood-2007-08-109330. Epub 2008 Jan 30.
9
Front-line TKI therapy for chronic-phase CML: the luxury of choice.慢性期慢性髓性白血病的一线酪氨酸激酶抑制剂治疗：选择的优势。
Oncology (Williston Park). 2012 Oct;26(10):908, 910, 912.
10
Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance.慢性髓性白血病中酪氨酸激酶抑制剂耐药的机制及克服耐药的最新治疗策略。
Hematology Am Soc Hematol Educ Program. 2009:461-76. doi: 10.1182/asheducation-2009.1.461.
引用本文的文献
1
An Evaluation of Rare Cancer Policies in Europe: A Survey Among Healthcare Providers.欧洲罕见癌症政策评估：医疗服务提供者调查
Cancers (Basel). 2025 Jan 7;17(2):164. doi: 10.3390/cancers17020164.
2
Molecular pathways and therapeutic strategies in dermatofibrosarcoma protuberans (DFSP): unravelling the tumor's genetic landscape.隆突性皮肤纤维肉瘤（DFSP）的分子途径和治疗策略：解析肿瘤的基因图谱
EXCLI J. 2024 May 14;23:727-762. doi: 10.17179/excli2024-7164. eCollection 2024.
3
Availability and Access to Orphan Drugs for Rare Cancers in Bulgaria: Analysis of Delays and Public Expenditures.保加利亚罕见癌症孤儿药的可及性与获取情况：延误及公共支出分析
Cancers (Basel). 2024 Apr 12;16(8):1489. doi: 10.3390/cancers16081489.
4
Emerging functions of the EGFR in cancer.EGFR 在癌症中的新兴功能。
Mol Oncol. 2018 Jan;12(1):3-20. doi: 10.1002/1878-0261.12155. Epub 2017 Nov 27.
5
Molecular and functional characterization of a new 3' end KIT juxtamembrane deletion in a duodenal GIST treated with neoadjuvant Imatinib.新辅助伊马替尼治疗的十二指肠胃肠道间质瘤中一种新的3'端KIT近膜区缺失的分子与功能特征
Oncotarget. 2017 Jul 18;8(34):56158-56167. doi: 10.18632/oncotarget.19341. eCollection 2017 Aug 22.
6
β-Catenin in desmoid-type fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression.β-连环蛋白在韧带样纤维瘤病中的作用：T41A 和 S45F 突变对蛋白质结构和基因表达影响的深入研究。
Mol Oncol. 2017 Nov;11(11):1495-1507. doi: 10.1002/1878-0261.12101. Epub 2017 Sep 29.
7
Rare cancers: Challenges & issues.罕见癌症：挑战与问题。
Indian J Med Res. 2017 Jan;145(1):17-27. doi: 10.4103/ijmr.IJMR_915_14.
8
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours.妇科癌症国际协作组（GCIG）第五届卵巢癌共识会议：罕见卵巢肿瘤的临床试验设计
Ann Oncol. 2017 Apr 1;28(4):718-726. doi: 10.1093/annonc/mdw662.
9
Recent developments in receptor tyrosine kinases targeted anticancer therapy.受体酪氨酸激酶靶向抗癌治疗的最新进展。
Vet World. 2016 Jan;9(1):80-90. doi: 10.14202/vetworld.2016.80-90. Epub 2016 Jan 29.
10
Advances in targeted therapies and new promising targets in esophageal cancer.食管癌靶向治疗的进展及新的有前景的靶点
Oncotarget. 2015 Jan 30;6(3):1348-58. doi: 10.18632/oncotarget.2752.
本文引用的文献
1
Regulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment.骨肿瘤微环境对骨保护素促肿瘤或抗肿瘤活性的调节
Biochim Biophys Acta. 2010 Jan;1805(1):17-24. doi: 10.1016/j.bbcan.2009.08.004. Epub 2009 Sep 3.
2
Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy.肺泡软组织肉瘤（ASPS）体内模型对抗血管生成治疗的治疗易损性。
J Pediatr Hematol Oncol. 2009 Aug;31(8):561-70. doi: 10.1097/MPH.0b013e3181a6e043.
3
Dermatofibrosarcoma protuberans: clinical, pathological, and genetic (COL1A1-PDGFB ) study with therapeutic implications.隆突性皮肤纤维肉瘤：临床、病理及遗传学（COL1A1-PDGFB）研究及其治疗意义
Histopathology. 2009 Jun;54(7):860-72. doi: 10.1111/j.1365-2559.2009.03310.x.
4
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.KRAS密码子61、146以及BRAF突变预示着KRAS密码子12和13野生型转移性结直肠癌患者对西妥昔单抗联合伊立替康耐药。
Br J Cancer. 2009 Aug 18;101(4):715-21. doi: 10.1038/sj.bjc.6605177. Epub 2009 Jul 14.
5
A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma.一种阻断致癌蛋白EWS-FLI1与RNA解旋酶A相互作用的小分子可抑制尤因肉瘤的生长。
Nat Med. 2009 Jul;15(7):750-6. doi: 10.1038/nm.1983. Epub 2009 Jul 5.
6
Response to imatinib plus sirolimus in advanced chordoma.晚期脊索瘤应用伊马替尼联合西罗莫司治疗的反应。
Ann Oncol. 2009 Nov;20(11):1886-94. doi: 10.1093/annonc/mdp210. Epub 2009 Jul 1.
7
Ewing's sarcoma: standard and experimental treatment options.尤因肉瘤：标准及实验性治疗方案
Curr Treat Options Oncol. 2009 Apr;10(1-2):126-40. doi: 10.1007/s11864-009-0104-6. Epub 2009 Jun 17.
8
Giant cell tumour of bone.骨巨细胞瘤
Curr Opin Oncol. 2009 Jul;21(4):338-44. doi: 10.1097/CCO.0b013e32832c951d.
9
Response of imatinib-resistant extra-abdominal aggressive fibromatosis to sunitinib: case report and review of the literature on response to tyrosine kinase inhibitors.伊马替尼耐药的腹外侵袭性纤维瘤病对舒尼替尼的反应：病例报告及酪氨酸激酶抑制剂反应的文献综述
Cancer Chemother Pharmacol. 2009 Aug;64(3):635-40. doi: 10.1007/s00280-009-1010-0. Epub 2009 Apr 29.
10
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.原发性肿瘤和转移灶中PTEN表达及KRAS突变对转移性结直肠癌患者从西妥昔单抗联合伊立替康治疗中获益的预测作用
J Clin Oncol. 2009 Jun 1;27(16):2622-9. doi: 10.1200/JCO.2008.20.2796. Epub 2009 Apr 27.
Zotero 插件